EN PL
CASE REPORT
Does early treatment of macrophage activation syndrome prevent fatal outcome in patients with severe systemic juvenile idiopathic arthritis?
 
More details
Hide details
 
Submission date: 2013-06-14
 
 
Final revision date: 2014-01-06
 
 
Acceptance date: 2014-02-10
 
 
Online publication date: 2014-03-23
 
 
Publication date: 2014-02-28
 
 
Reumatologia 2014;52(1):82-85
 
KEYWORDS
TOPICS
ABSTRACT
Macrophage activation syndrome (MAS), a rare complication of various diseases, mainly systemic inflammatory connective tissue disorders, is being increasingly recognized. Most frequently MAS occurs in systemic juvenile idiopathic arthritis (sJIA), yet description of typical clinical features is challenging. Prognosis of the syndrome is often poor therefore prompt diagnosis and appropriate medical treatment are critical for survival.
We report the case of MAS diagnosed in a 7-year-old boy with severe generalized sJIA presenting description of our dilemmas associated with the diagnosis. We identified the condition as MAS on the basis of criteria defined by Ravelli et al. To make diagnosis of MAS was difficult, especially because some clinical symptoms are characteristic both for MAS and sJIA. Owing to deterioration of a general condition of the patient we took the risk of including treatment with cyclosporine. This treatment significantly improved the condition of the child and in our opinion prevented a fatal outcome.
REFERENCES (11)
1.
Gietka P, Wieteska-Klimczak A, Smorczewska-Kiljan A, Rutkow-ska-Sak L. Reactive hemophagocytic syndromes in children with rheumatic diseases. Reumatologia 2011; 49: 96-107.
 
2.
Wulffraat NM. Defining criteria for macrophage activation syndrome, a process towards early recognition and treatment. J Rheumatol 2011; 38: 593-594.
 
3.
Gurion R, Lehman TJ, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam 2012; 2012: 271569.
 
4.
Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012; 13: 289-298.
 
5.
Ravelli A, Jung L. Macrophage activation syndrome. Medscape Reference 2010; 6:.
 
6.
Villanueva J, Lee S, Giannini EH, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7: R30-37.
 
7.
Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146: 598-604.
 
8.
Zoń-Giebel A, Giebel S. Zespół aktywacji makrofagów – reaktywna postać limfohistiocytozy hemofagocytarnej. Reumatologia 2008; 46: 21-26.
 
9.
Davì S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38: 764-768.
 
10.
Davi S, Lattanzi B, Demirkaya E. Toward the development of new diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Paediatr Rheum 2012; 1: 1-7.
 
11.
Ravelli A, Davi S, Parodi A. Macrophage activation syndrome workup. Medscape Reference 2012; 12. Available at: http://emedicine.medscape.com/....
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top